Allantoin is under clinical development by Paradigm Therapeutics and currently in Phase III for Epidermolysis Bullosa. According to GlobalData, Phase III drugs for Epidermolysis Bullosa have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Allantoin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Allantoin overview

Allantoin (SD-101) is under development for the treatment of skin blistering and lesions associated with epidermolysis bullosa (EB). The drug candidate is administered through topical route. It was under development for the treatment of diabetic foot ulcers.

Paradigm Therapeutics overview

Paradigm Therapeutics is an aclinical-stage pharmaceutical company focused on developing critical medical needs in the treatment of rare diseases in fields of dermatology like Epidermolysis Bullosa and other diseases. The company is headquartered in Mt. Pleasant, South Carolina, the US.

For a complete picture of Allantoin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.